3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Interventions
fludarabine phosphate
90
Cyclophosphamide
85
Mycophenolic Acid
67
Peripheral Blood Stem Cell Transplantation
65
Whole-Body Irradiation
59
Tacrolimus
58
Cyclosporine
46
Busulfan
45
Antilymphocyte Serum
39
fludarabine
35
Filgrastim
35
Melphalan
33
Methotrexate
28
Radiotherapy
26
Granulocyte Colony-Stimulating Factor
20
Sirolimus
17
Methylprednisolone
17
Etoposide
17
Cord Blood Stem Cell Transplantation
17
Rituximab
14
Stem Cell Transplantation
13
Alemtuzumab
13
thymoglobulin
11
sargramostim
11
Cyclosporins
11
Therapeutics
10
Flow Cytometry
10
Cytarabine
10
plerixafor
8
Thiotepa
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
angiotensin I (1-7)
×
Plasma cell
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled